


PRODUCT INFORMATION



PF 9601N

Item No. 34258

CAS Registry No.: 133845-63-3
Formal Name: 5-(phenylmethoxy)-N-2-propyn-1-yl-1H-indole-2-methanamine
MF: C₁₉H₁₈N₂O
FW: 290.4
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PF 9601N is supplied as a solid. A stock solution may be made by dissolving the PF 9601N in the solvent of choice, which should be purged with an inert gas. PF 9601N is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of PF 9601N in ethanol is approximately 20 mg/ml and approximately 30 mg/ml in DMSO and DMF.

PF 9601N is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, PF 9601N should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. PF 9601N has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

PF 9601N is an inhibitor of monoamine oxidase B (MAO-B).¹ It selectively inhibits MAO-B in mouse brain homogenates *ex vivo* (ID₅₀ = 381 nmol/kg) and prevents MPTP-induced reductions in dopamine levels in the striatum of 8- to 9-week-old mice when administered at doses ranging from 29.5 to 8.47 μmol/kg. PF 9601N (0.027 μmol/kg) prevents MPTP-induced lesions in 9- to 10-month-old mice. It also increases the duration of contralateral rotational behavior induced by L-DOPA (Item No. 13248) in a rat model of Parkinson's disease induced by 6-OHDA (Item No. 25330) when administered at doses of 40 and 60 mg/kg.²

References

1. Perez, V. and Unzeta, M. PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice. *Neurochem. Int.* **42**(3), 221-229 (2003).
2. Prat, G., Pérez, V., Rubi, A., *et al.* The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats. *J. Neural Transm. (Vienna)* **107**(4), 409-417 (2000).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/18/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM